Role of glyoxalase-1 in Alzheimer's disease pathogenesis and therapy

乙二醛酶-1在阿尔茨海默病发病机制和治疗中的作用

基本信息

批准号：
10614421
负责人：
Swati S More
金额：
$ 38.5万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-15 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10614421
关键词：
Address Advanced Glycosylation End Products Affect Alzheimer&apos s Disease Alzheimer&apos s disease brain Alzheimer&apos s disease model Alzheimer&apos s disease pathology Alzheimer&apos s disease therapeutic Alzheimer&apos s disease therapy Amyloid Amyloid beta-Protein Amyloid deposition Antioxidants Attenuated Biological Availability Brain Brain region Catabolism Cells Cerebral cortex Cerebrum Clinical Clinical Trials Cognition Cognitive deficits Data Development Disease Disease Progression Drug Kinetics Drug Metabolic Detoxication Effectiveness Elderly Enzymes Free Radicals Functional disorder Future Gamma-glutamyl transferase Gastrointestinal tract structure Generations Glutathione Glutathione Metabolism Pathway Goals Hippocampus Homeostasis Impaired cognition In Vitro Inflammation Lactoylglutathione Lyase Lead Learning Mediator Metabolic Mus Nerve Degeneration Neurodegenerative Disorders Neurofibrillary Tangles Neurons Oral Oxidative Stress Pathogenesis Pathogenicity Pathologic Pathology Pathway interactions Patients Pharmaceutical Chemistry Pharmaceutical Preparations Plasma Prevalence Process Prodrugs Proteins Proteolysis Research Resistance Role Senile Plaques Sulfhydryl Compounds Supplementation Symptoms System Tauopathies Testing Therapeutic Toxic effect Treatment Efficacy abeta accumulation abeta deposition aging brain amyloid pathology clinical development extracellular glutathione analog glycation improved innovation mimetics molecular targeted therapies mouse model neuron loss neuropathology neuroprotection new therapeutic target novel novel therapeutics pre-clinical preclinical evaluation preclinical study prevent progressive neurodegeneration prospective prototype rational design restoration sugar tau Proteins tau aggregation tau-1 therapy development tool

项目摘要

PROJECT SUMMARY Alzheimer’s disease (AD) is the most common progressive neurodegenerative disease responsible for cognitive impairment in elderly subjects. In AD, loss of neurons in the cerebral cortex and hippocampus is accompanied by extracellular deposition of Aβ plaques and neurofibrillary tangles of hyper phosphorylated tau. Currently, other than symptomatic therapies to maintain cerebrocortical activity and to modulate learning/cognition, there are no ways to stop the progression of the disease. Given the increased prevalence of the disease, there is an urgent need to develop therapies that can stop or slow down the progression of AD. Increased oxidative stress is implicated in the onset and progression of AD. Free radicals and reactive dicarbonyls under oxidative stress conditions irreversibly modify proteins forming proteolysis-resistant Advanced Glycation End products (AGEs) and have been implicated as causative agents in AD related cell dysfunction and degeneration. Normally, the Glyoxalase enzyme system (Glo-1), combined with glutathione (GSH), reduces oxidative stress and reactive dicarbonyls responsible for AGE formation. However, reduction in brain GSH levels increases oxidative stress and renders Glo-1 inactive. Unfortunately, GSH supplementation is highly inefficient as GSH is not orally bioavailable and is unstable in plasma due to the efficient catabolism by γ-glutamyl transpeptidase (GGT). To improve the utility of GSH supplementation for AD, we have developed a GSH analog (ψ-GSH) that is resistant to GGT. Our studies show that ψ-GSH accumulates in the brain more efficiently than GSH and protects AD mouse model from onset of AD pathology. In the proposed studies, we will test the hypothesis that the GGT- resistant GSH-mimetic compounds will reduce oxidative stress and AGEs and slow/stop the progression of AD pathology in symptomatic stages of AD mouse models, including progressive neurodegeneration. Second, we aim to determine the role of Glo-1 enzyme system in AD pathogenesis and progression, and determine if Glo-1 enzyme is required for ψ-GSH dependent neuroprotection. Finally, we propose to develop prodrugs of ψ-GSH that will be more bioavailable than ψ-GSH. The results of these studies will form a basis for rational design of druggable Glo-1 substrates and will provide strong justification for their continued development.

项目概要阿尔茨海默病 (AD) 是最常见的进行性神经退行性疾病，与认知能力相关老年受试者的损伤伴随着大脑皮层和海马神经元的损失。通过 Aβ 斑块的细胞外沉积和过度磷酸化 tau 的神经原纤维缠结目前，其他。除了维持大脑皮质活动和调节学习/认知的对症治疗之外，没有其他方法鉴于该疾病患病率的增加，迫切需要找到阻止该疾病进展的方法。需要开发能够阻止或减缓 AD 进展的疗法。参与氧化应激下自由基和活性二羰基的发生和进展。条件不可逆地改变蛋白质，形成抗蛋白水解的高级糖基化终产物 (AGE) 并被认为是 AD 相关细胞功能障碍和退化的致病因素。乙二醛酶系统 (Glo-1) 与谷胱甘肽 (GSH) 结合，可减少氧化应激和反应性负责 AGE 形成的二羰基化合物然而，大脑 GSH 水平的降低会增加氧化应激。不幸的是，GSH 补充剂的效率非常低，因为 GSH 不是口服的。具有生物利用度，但由于 γ-谷氨酰转肽酶 (GGT) 的有效分解代谢，在血浆中不稳定。为了提高 GSH 补充剂对 AD 的效用，我们开发了一种具有抗药性的 GSH 类似物 (ψ-GSH) 我们的研究表明，ψ-GSH 在大脑中的积累比 GSH 更有效，可以保护 AD。 AD 病理发作的小鼠模型在拟议的研究中，我们将检验 GGT- 的假设。抗性 GSH 模拟化合物将减少氧化应激和 AGE，并减缓/阻止 AD 的进展 AD 小鼠模型症状阶段的病理学，包括进行性神经变性其次，我们。旨在确定 Glo-1 酶系统在 AD 发病机制和进展中的作用，并确定 Glo-1 是否最后，我们建议开发ψ-GSH 的前药。这些研究的结果将成为合理设计的基础。可药物化的 Glo-1 底物，并将为其持续开发提供强有力的理由。

项目成果

期刊论文数量（6）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Sulfur-containing therapeutics in the treatment of Alzheimer's disease.

治疗阿尔茨海默病的含硫疗法。

DOI：
发表时间：
2021-02
期刊：
影响因子：
0
作者：
Zhu, Haizhou;Dronamraju, Venkateshwara;Xie, Wei;More, Swati S
通讯作者：
More, Swati S

Geometric Isomer of Guanabenz Confers Hepatoprotection to a Murine Model of Acetaminophen Toxicity.

胍那苯的几何异构体对乙酰氨基酚毒性小鼠模型具有肝保护作用。

DOI：
发表时间：
2023-07-17
期刊：
影响因子：
4.1
作者：
Xie, Wei;Jiang, Rongrong;Xie, Jiashu;Vince, Robert;More, Swati S
通讯作者：
More, Swati S

Role of 3-Mercaptopyruvate Sulfurtransferase (3-MST) in Physiology and Disease.

3-巯基丙酮酸硫转移酶 (3-MST) 在生理学和疾病中的作用。

DOI：
发表时间：
2023-03-01
期刊：
影响因子：
0
作者：
Rao, Swetha Pavani;Dobariya, Prakashkumar;Bellamkonda, Harshini;More, Swati S
通讯作者：
More, Swati S

Deletion of Glyoxalase 1 exacerbates acetaminophen-induced hepatotoxicity in mice.

乙二醛酶 1 的缺失会加剧对乙酰氨基酚诱导的小鼠肝毒性。

DOI：
发表时间：
2023-12-23
期刊：
影响因子：
0
作者：
Dobariya, Prakashkumar;Xie, Wei;Rao, Swetha Pavani;Xie, Jiashu;Seelig, Davis M;Vince, Robert;Lee, Michael K;More, Swati S
通讯作者：
More, Swati S

Dipeptide of ψ-GSH Inhibits Oxidative Stress and Neuroinflammation in an Alzheimer's Disease Mouse Model.

α-GSH 二肽抑制阿尔茨海默病小鼠模型中的氧化应激和神经炎症。

DOI：
发表时间：
2022-05-28
期刊：
影响因子：
0
作者：
Raza, Abbas;Xie, Wei;Kim, Kwan;Dronamraju, Venkateshwara Rao;Williams, Jessica;Vince, Robert;More, Swati S
通讯作者：
More, Swati S